Regents of the University of California’s Allogene Therapeutics ALLO Stock Holding History

Regents of the University of California’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-675,743	Closed	-$23.9M	–	35
2021 Q1	$23.9M	Sell	675,743 -224,400	-25%	-$7.57M	3.11%	3
2020 Q4	$22.7M	Buy	+900,143	New	+$29.3M	3.28%	3
2020 Q3	–	Sell	-1,279,281	Closed	-$54.8M	–	30
2020 Q2	$54.8M	Sell	1,279,281 -1,071,649	-46%	-$38.8M	7.69%	2
2020 Q1	$47.2M	Hold	2,350,930	–	–	7.03%	2
2019 Q4	$61.1M	Buy	+2,350,930	New	+$64.7M	32.21%	2

Other funds holding ALLO

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Regents of the University of California's ALLO Position: Q2 2021 in Review

Regents of the University of California sold out of Allogene Therapeutics (ALLO) in Q2 2021, closing a stake of 675,743 shares — an estimated $23.9M sold.

Regents of the University of California first reported a position in ALLO in Q4 2019 and held it in 5 quarters. The position peaked at $61.1M in Q4 2019. 182 funds tracked by Wall St. Rank hold ALLO as of Q2 2021.

Regents of the University of California reported no remaining Allogene Therapeutics position as of Q2 2021 after selling out during the quarter.
Regents of the University of California sold 675,743 Allogene Therapeutics shares in Q2 2021, an estimated $23.9M.
Regents of the University of California first reported a position in Allogene Therapeutics in Q4 2019 and held it in 5 quarters.
Regents of the University of California's Allogene Therapeutics position peaked at $61.1M in Q4 2019.
182 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2021.

Based on Regents of the University of California's 13F filing for Q2 2021, filed 27 Jul 2021.